Streetbeat News

Earnings

LGND

Ligand Pharmaceuticals has reaffirmed its financial guidance for FY24, projecting EPS of $4.25-$4.75 and total revenue of $130M-$142M. This guidance, initially introduced during its Investor and Analyst Day on December 12, 2023, includes expected royalties of $90M-$95M, Captisol sales of $25M-$27M, and contract revenue of $15M-$20M.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 12:12 pm

RCM

R1 RCM projects its FY24 revenue to be in the range of $2.625 billion to $2.675 billion, which is below the estimated $2.69 billion. The company also forecasts GAAP operating income between $105 million to $135 million and adjusted EBITDA between $650 million to $670 million.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 12:12 pm

STGW

Stagwell forecasts a 5%-7% organic net revenue growth for 2024, with an adjusted EPS range of $0.75-$0.88, which is below the estimated $0.91.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 12:11 pm

APPS

CAMP

FIVN

The article highlights the top 3 oversold tech stocks in the information technology sector, suggesting they may be undervalued opportunities for investors. These include Five9, Inc. (FIVN), CalAmp Corp. (CAMP), and Digital Turbine, Inc. (APPS), each with an RSI below 30, indicating they are oversold. Recent financial results and market actions are discussed for each company, providing insight into their current stock performance and potential for short-term recovery.

Portfolio Pulse from Avi Kapoor

February 27, 2024 | 12:10 pm

DKL

Delek Logistics Partners (DKL) reported Q4 earnings of $1.46 per share, surpassing the $0.89 estimate, a 48.98% increase from last year. However, their Q4 sales of $254.10M fell short of the $278.26M estimate, marking a 5.56% decrease from the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 12:10 pm

RCM

R1 RCM (NASDAQ:RCM) reported Q4 sales of $575.10M, missing the consensus estimate of $578.69M by 0.62%. This represents a 7.94% increase over the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 12:10 pm

TREE

LendingTree provided its Q1 revenue forecast in the range of $158M-$168M, slightly below the estimated $165.235M. Additionally, the company projects its 2024 revenue to be between $650M-$690M, indicating a potential year-over-year change ranging from a 3% decline to a 3% increase, which falls short of the estimated $715.61M.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 12:08 pm

FULC

Fulcrum Therapeutics (NASDAQ:FULC) reported Q4 GAAP EPS of $(0.40), surpassing the $(0.43) estimate, and sales of $871.00K, exceeding the $460.00K estimate. Year-over-year, this represents a 20% decrease in losses and a 27.15% increase in sales. The company's cash balance of $236.2M is expected to provide a cash runway into 2026.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 12:08 pm

APLS

Apellis Pharmaceuticals (NASDAQ:APLS) reported Q4 earnings with a per-share loss of $(0.73), missing the $(0.69) estimate, but saw sales of $146.38M, exceeding the $143.59M estimate. This represents a significant improvement over the previous year, with a 51.33% decrease in losses and a 545.89% increase in sales.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 12:07 pm

SRE

Sempra has updated its EPS guidance for 2024 to $4.60-$4.90, up from the previous $4.44-$4.74, and set its 2025 EPS guidance at $4.90-$5.25. The company also reaffirmed its long-term EPS growth rate of 6-8%.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 12:07 pm